



Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

December 1, 2022

PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the BofA Securities 2022 Biotech SMID Cap Conference, which is taking place virtually from December 7-8.

Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on December 7.

A live audio webcast of the presentation will be available [here](#) at 2:20 pm ET on Wednesday, December 7 and an archived version of the webcast will be available following the presentation on the Investor section of the Company's [website](#).


About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company's wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

CONTACT:

Investors and Media

Meg Dodge
Krystal Biotech
mdodge@krystalbio.com



Source: Krystal Biotech, Inc.